In Brief MicroStrategy might replace Moderna in the Nasdaq 100, riding high on its Bitcoin-driven stock surge. Nasdaq’s classification rules currently list MicroStrategy as a tech stock, bypassing restrictions on financial companies. Analysts Eric Balchunas and James Seyffart see reclassification risks but expect inclusion if no changes occur before March. According to Eric Balchunas and…
Read more
